



April 12, 2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 12, 2023-- [Veracyte, Inc.](#) (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company's Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company's Decipher Prostate Genomic Classifier, which helps inform treatment decisions for men with prostate cancer.

"The volume and quality of Decipher data being presented at AUA 2023 reinforce Veracyte's ongoing commitment to evidence-based care and to advancing our understanding of urologic cancers. We are particularly excited about new data demonstrating the real-world impact of our Decipher Prostate test on patient care and outcomes," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology.

Following are details of the Decipher abstracts accepted for presentation at the AUA 2023 meeting:

Date/Time: April 28, 2023, 10:00-10:10 a.m. CT

Title: [Molecular Correlates with PSMA Expression in Prostate Cancer](#) (#PD04-04)

Format: Podium Session

Presenter: Adam Weiner, M.D., UCLA Health

Location: McCormick Place, S401C

Date/Time: April 28, 2023, 1:00-3:00 p.m. CT

Title: [Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in a Large-Scale Real-World Dataset](#) (#MP17-02)

Format: Moderated Poster Session

Presenter: Michael Leapman, M.D., Yale University School of Medicine

Location: McCormick Place, S504

Date/Time: April 28, 2023, 1:00-3:00 p.m. CT

Title: [Development of a Longitudinal Prostate Cancer Transcriptomic and Real-World Clinical Data Linkage](#) (#MP17-09)

Format: Moderated Poster Session

Presenter: Michael Leapman, M.D., Yale University School of Medicine

Location: McCormick Place, S504

Date/Time: April 28, 2023, 1:00-3:00 p.m. CT

Title: [Differential Transcriptomic Indicators of Potential Therapeutic Response to Targeted Therapy for AJCC IIC+ Localized Prostate Cancer With Decipher >0.95](#) (#MP17-01)

Format: Moderated Poster Session

Presenter: Eric Li, M.D., Einstein Healthcare Network

Location: McCormick Place, S504

Date/Time: April 29, 2023, 3:30-5:30 p.m. CT

Title: [Use of Decipher Prostate Biopsy Test in Men With Favorable Risk Disease Undergoing Conservative Management in the SEER Registry](#) (#MP44-17)

Format: Moderated Poster Session

Presenter: Alec Zhu, MD, Weill Cornell Medical College

Location: McCormick Place, S403

Date/Time: April 30, 2023, 3:40-3:50 p.m. CT

Title: [A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients](#) (#PD36-02)

Format: Podium Session

Presenter: Joep de Jong

Location: McCormick Place, S501A

Date/Time: April 30, 2023, 5:20-5:30 p.m. CT

Title: [Biology and performance of pre- and post-pembrolizumab \(Pembro\) Vesical Imaging-Reporting and Data System \(VI-RADS\) to predict the pathological response in muscle-invasive urothelial bladder cancer \(MIBC\)](#); Full data analysis from a clinical trials pipeline (#LBA03-12)

Format: Podium Session

Presenter: Andrea Necchi, M.D., Vita-Salute San Raffaele University

Location: McCormick Place, S404A

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, that the Decipher Prostate test may have a real-world impact on patient care and outcomes. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at <https://investor.veracyte.com/>. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230412005237/en/): <https://www.businesswire.com/news/home/20230412005237/en/>

Investors:

Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:

Tracy Morris
Vice President of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.